From Cancer Diagnosis to Wedding Plans: Mrinali Dhembla’s Inspiring Journey

After getting engaged, journalist Mrinali Dhembla anticipated the joyous words of “I do.” Instead, her world was upended when she heard the life-altering diagnosis: “You have cancer.”

At just 27 years old, Dhembla faced an aggressive Stage 3 rectal cancer that had already metastasized to her spine. This diagnosis reflects a troubling trend, as colorectal cancer rates are rising among adults under 50, a demographic traditionally seen as low-risk. Dhembla’s experience serves as a stark reminder of the unexpected challenges that can arise in life, particularly for those who might dismiss seemingly minor health disturbances.

Before receiving her diagnosis, Dhembla had ignored symptoms like rectal bleeding, chronic constipation, and low-grade fevers, mistakenly attributing them to less serious issues. It was only through genetic testing that she learned she had Lynch syndrome, a hereditary condition that predisposes individuals to various cancers. Dr. Nicholas Hornstein, an assistant professor at the Northwell Health Cancer Institute, likens the genes responsible for DNA repair to a spellcheck system. In individuals with Lynch syndrome, this system is compromised, allowing DNA errors to accumulate and potentially lead to cancer.

Individuals with Lynch syndrome should begin screening for colorectal cancer much earlier than the average population—ideally between the ages of 20 and 25. However, Dhembla was unaware of her condition and did not undergo the necessary surveillance prior to her diagnosis.

Fortunately, Dhembla’s specific cancer profile made her a prime candidate for a cutting-edge dual-immunotherapy treatment involving nivolumab and ipilimumab. This regimen, recently approved by the Food and Drug Administration for advanced cancers, represents a significant advancement in cancer treatment, particularly for tumors characterized as “MSI-high,” which are highly susceptible to immunotherapy. Dr. Hornstein noted that only about 15% of all colorectal cancers fall into this category, but the percentage is notably higher among younger patients and those with Lynch syndrome.

The dual immunotherapy approach empowers the immune system to combat cancer cells more effectively, breaking through the protective barriers tumors often erect. Remarkably, after just three infusions over four months, Dhembla’s scans and biopsies revealed no detectable signs of cancer. Her circulating tumor DNA levels plummeted from 300 to zero, leading to her being declared cancer-free in July 2025. Dr. Hornstein emphasized that Dhembla’s immune system achieved what traditional treatments might not have, highlighting the potential of precision medicine.

Had Dhembla followed the conventional treatment pathway, she would have faced complex spinal surgery with significant risks and the possibility of enduring long-term changes to her quality of life, including the need for a permanent colostomy bag. Instead, her journey has allowed her to resume wedding planning with her fiancé, Chris, although they opted to postpone their wedding to allow time for emotional recovery from the ordeal.

Post-treatment, Dhembla manages side effects such as fatigue and thyroid dysfunction, but she has adapted well to her new routine, which includes regular monitoring with a team of specialists. Dhembla’s vigilance reflects a broader trend in cancer survivorship, where ongoing surveillance is critical for early detection of any potential recurrence.

As she embraces her new life in New York and resumes wedding planning, Dhembla remains committed to her health journey. She and Chris have taken several international trips since her recovery, a testament to her newfound perspective on life, love, and resilience. “Even though my cancer journey was short, it left a lasting impact. I need time to emotionally and mentally recover from it,” she remarked, embodying the strength and hope that many cancer survivors strive to maintain.

Dhembla’s story shines a light on the importance of awareness regarding genetic predispositions to cancer, the evolution of treatment options, and the significance of resilience in the face of life-altering challenges. Through her experience, she offers a poignant reminder that early detection and innovative therapies can lead to remarkable outcomes and renewed hope for a future filled with possibilities.

Reviewed by: News Desk
Edited with AI assistance + Human research

Source